TABLE 1.
Characteristics of the real‐world cohort of patients with aNSCLC included in this study, overall and by tertile of scan frequency
| Total | Frequency of imaging assessment tertile a | |||
|---|---|---|---|---|
| Low | Medium | High | ||
| N = 3118 | n = 1034 | n = 1027 | n = 1057 | |
| Age at advanced diagnosis, median [IQR] | 67.0 [60.0;74.0] | 69.0 [61.0;75.0] | 67.0 [59.0;74.0] | 66.0 [59.0;73.0] |
| Year of advanced diagnosis | ||||
| <2014 | 686 (22.0%) | 278 (26.9%) | 224 (21.8%) | 184 (17.4%) |
| 2015–2017 | 1999 (64.1%) | 663 (64.1%) | 667 (64.9%) | 669 (63.3%) |
| 2018 | 433 (13.9%) | 93 (9.0%) | 136 (13.2%) | 204 (19.3%) |
| Sex | ||||
| Female | 1607 (51.5%) | 554 (53.6%) | 513 (50.0%) | 540 (51.1%) |
| Male | 1511 (48.5%) | 480 (46.4%) | 514 (50.0%) | 517 (48.9%) |
| Race | ||||
| White | 2257 (72.4%) | 731 (70.7%) | 741 (72.2%) | 785 (74.3%) |
| Black, Afr. Am | 204 (6.5%) | 75 (7.3%) | 61 (5.9%) | 68 (6.4%) |
| Asian | 109 (3.5%) | 54 (5.2%) | 30 (2.9%) | 25 (2.4%) |
| Other | 290 (9.3%) | 96 (9.3%) | 97 (9.4%) | 97 (9.2%) |
| Not reported | 258 (8.3%) | 78 (7.5%) | 98 (9.5%) | 82 (7.8%) |
| Practice type | ||||
| Academic | 95 (3.0%) | 30 (2.9%) | 34 (3.3%) | 31 (2.9%) |
| Community | 3023 (97.0%) | 1004 (97.1%) | 993 (96.7%) | 1026 (97.1%) |
| Smoking history | ||||
| Yes | 2498 (80.1%) | 798 (77.2%) | 824 (80.2%) | 876 (82.9%) |
| No | 609 (19.5%) | 233 (22.5%) | 199 (19.4%) | 177 (16.7%) |
| Unknown/Not doc. | 11 (0.4%) | 3 (0.3%) | 4 (0.4%) | 4 (0.4%) |
| Disease stage | ||||
| Stage I | 262 (8.4%) | 112 (10.8%) | 79 (7.7%) | 71 (6.7%) |
| Stage II | 184 (5.9%) | 72 (7.0%) | 52 (5.1%) | 60 (5.7%) |
| Stage III | 578 (18.5%) | 256 (24.8%) | 183 (17.8%) | 139 (13.2%) |
| Stage IV | 2044 (65.6%) | 573 (55.4%) | 694 (67.6%) | 777 (73.5%) |
| Other | 50 (1.6%) | 21 (2.0%) | 19 (1.9%) | 10 (0.9%) |
| Histology | ||||
| Non‐squamous | 2432 (78.0%) | 811 (78.4%) | 806 (78.5%) | 815 (77.1%) |
| Squamous | 566 (18.2%) | 184 (17.8%) | 181 (17.6%) | 201 (19.0%) |
| NOS | 120 (3.8%) | 39 (3.8%) | 40 (3.9%) | 41 (3.9%) |
| Therapy class in first‐line | ||||
| Platinum‐based | 1150 (36.9%) | 320 (30.9%) | 374 (36.4%) | 456 (43.1%) |
| PD‐1/PD‐L1‐based | 761 (24.4%) | 240 (23.2%) | 239 (23.3%) | 282 (26.7%) |
| Anti‐VEGF‐containing | 602 (19.3%) | 183 (17.7%) | 212 (20.6%) | 207 (19.6%) |
| EGFR TKIs | 423 (13.6%) | 222 (21.5%) | 132 (12.9%) | 69 (6.5%) |
| ALK inhibitors | 95 (3.0%) | 38 (3.7%) | 37 (3.6%) | 20 (1.9%) |
| Single agent chemother. | 63 (2.0%) | 25 (2.4%) | 26 (2.5%) | 12 (1.1%) |
| Other | 24 (0.8%) | 6 (0.6%) | 7 (0.7%) | 11 (1.1%) |
Abbreviations: ALK, anaplastic lymphoma kinase; aNSCLC, advanced non‐small cell lung cancer; EGFR, epidermal growth factor receptor; IQR, interquartile range; NOS, not otherwise specified; PD‐(L)1, programmed death (ligand) 1; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
a
Imaging frequency tertile of low, medium, or high corresponds to mean weeks between assessment time points being >11.9, 8.6–11.9, and 3.5–8.5 respectively.